Navigation Links
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Date:4/3/2011

alized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, having recently completed phase 2b clinical development (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERS

Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
2. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
3. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
4. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
8. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
9. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
11. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... Research and Markets ( ... "Endoscopy Global Market - Forecast to 2020" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The global endoscopy market ... 2019 growing at around 7.0% CAGR from 2014 ... growth are aging population, increase in cancer, diabetes, ...
(Date:4/27/2015)... 27, 2015  CytoSorbents Corporation (NASDAQ: CTSO ... its CytoSorb® extracorporeal cytokine adsorber to purify blood ... Dr. Joerg Scheier , M.D. as European ... a specialist in intensive care medicine and anesthesiology, ... in treating critically-ill patients and in the design ...
(Date:4/27/2015)... , April 27, 2015 China Jo-Jo ... " China Jo-Jo "), a leading China-based retail and ... through its online and retail pharmacies, today announced its ... Pharmacy") has signed a new sales incentive agreement with ... in China of Pfizer Inc. ...
Breaking Medicine Technology:Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 2CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 3CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 4CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 5China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 2China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 3China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 4
(Date:4/27/2015)... MN (PRWEB) April 27, 2015 Based ... Secura Consultants is one of the few insurance marketing ... in the income and asset protection markets as well ... the industry has afforded Secura Consultants the opportunity to ... to make doing business easier and quicker. , An ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 According to ... and Craniofacial Research), after chronic back pain, TMJ disorders ... resulting in pain and disability. In addition, the report ... percent of the population, costing an estimated 4 billion ... million Americans suffering from seemingly unrelated symptoms such as ...
(Date:4/27/2015)... 2015 The Doctors on Liens ... of personal injury attorneys with the best doctors working on ... steady growth throughout their history and that trend continues with ... and his team in the Tujunga / Sunland ... massage therapist, patients can find comprehensive care and detailed documentation ...
(Date:4/27/2015)... 2015 TayganPoint Consulting Group, a ... announce their sponsorship of Girls on the Run ... on the Run is a youth development program ... The program is delivered through an interactive curriculum ... to develop the whole girl – physically, mentally, ...
(Date:4/27/2015)... New York, NY (PRWEB) April 27, 2015 ... Jimmy Buffett tickets at the Alpine Valley Music ... in the Elkhart, Wisconsin and Albuquerque, New Mexico area ... in their neck of the woods. Buffett will ... News in Wisconsin. His tour stops during the ...
Breaking Medicine News(10 mins):Health News:Simplified Solutions Now Makes Disability Insurance Business With Secura Consultants Even Easier! 2Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:TayganPoint Consulting Group Announces Sponsorship of Girls on the Run 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2
... and format for its “OneMedForum 2009” finance ... in San Francisco at the Sir Francis ... and disrupters” affecting each of the following ... System and Neurostimulation; Cardiology; Urology and Sexual ...
... Farms, Inc.,(OTC Bulletin Board: USFM), a diversified commercial ... Network (OTCFN), a division of,National Financial Communications Corp. ... The OTCFN Report details US Farms, Inc.,s current ... growth and,management team. Interested parties can download ...
... Genaera Corporation (Nasdaq: GENR ) today announced ... to present at the 2008 RBC Capital Markets Healthcare Conference. ... discussion of obesity, entitled, "Shrinking The Obesity Epidemic," and will ... York on Wednesday, December 11 at 11:00 a.m. ET. , ...
... WASHINGTON, Dec. 4 Stem cells derived from bone marrow ... disease called epidermolysis bullosa (EB), a disorder characterized by extraordinarily ... Blood , the official journal of the American Society of ... bullosa is a disorder characterized by extraordinarily fragile skin and ...
... the Nation in Giving as Demand for Nonprofit Services Peaks ... More than half of Coloradans report that they will ... during the economic downturn, according to " Generous Colorado: Why ... which reflects data from surveys conducted October 2008. With demand ...
... Empowerment Fund by purchasing the Green Bracelet at www.simmonsjewelryco.com , ... The Diamond Empowerment Fund (D.E.F.), Hearst Magazines, and ... exclusive "Empowerment for Africa" dinner held at Hearst Tower in ... co-founder Russell Simmons and special guests including ...
Cached Medicine News:Health News: OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 3Health News:Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 3Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 4Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 2Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 3Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 4Health News:On World AIDS Day, Russell Simmons and Special Guests Attended 'Empowerment for Africa' Dinner 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: